NTRK1 and neuroblastoma: This assay was developed based on the discovery that TrkAIII is a potentially frequent and actionable oncogenic equivalent to TrkA-fused genes in neuroblastomas and other tumor types and is highly efficient, reproducible, and specific in detecting as few as 10 TrkAIII copies in complex tumor cDNAs.